港股異動丨IGG飆升超20%創逾3個月新高,上半年盈利倍增至3.3億港元
IGG(0799.HK)逆勢放量大升,盤中一度升超20%至3.21港元,股價創逾3個月新高。公司昨晚公佈業績顯示,得益於兩款策略大作——《Doomsday:Last Survivors》與《Viking Rise》的新鋭發展,以及APP業務的亮眼表現,推動公司2024年上半年實現收入27.35億港元,同比增長9%;上半年利潤倍增,實現盈利3.3億港元。董事會宣派中期股息每股8.5港仙,約佔上半年溢利的30%。回購方面,上半年累計回購金額近3300萬港元。集團上半年宣派股息及回購金額合計約佔上半年溢利的40%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.